The resurgence of estrogens in the treatment of castration-resistant prostate cancer

Krishna H. Moorthy, G. G.Laxman Prabhu, P. Venugopal

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Use of exogenous estrogens in manipulating the androgenestrogen equilibrium was one of the earliest therapeutic strategies developed to treat prostate cancer which followed close on heels the discovery of hormone dependence of this tumor. Despite its well-documented benefit, estrogen therapy fell out of favor with the advent of other forms of androgen deprivation therapy (ADT) as the former registered a higher incidence of cardiovascular complications and poorer overall survival. Clearer understanding of the mechanism of action of estrogen coupled with the adoption of alternative routes of administration has triggered a renewed interest in estrogen therapy. Since then, many studies have not only proved the therapeutic benefit of estrogens but also explored the ways and means of minimizing the dreaded side effects deterring its use. Further, the fact that estrogen therapy offered a clear advantage of reduced cost of treatment over other treatments has led many countries to readopt it in the treatment of advanced prostatic cancer. We reviewed the published data on the use of estrogens in CRPC, which may affect its revival as an efficacious treatment option having minimal side effects, with modified dosage and route of administration. Estrogen therapy would be a less expensive option having equivalent or even better therapeutic effect than ADT in advanced carcinoma of prostate.

Original languageEnglish
Pages (from-to)189-196
Number of pages8
JournalIndian Journal of Urology
Volume35
Issue number3
DOIs
Publication statusPublished - 01-07-2019

Fingerprint

Castration
Prostatic Neoplasms
Estrogens
Therapeutics
Androgens
Heel
Therapeutic Uses
Health Care Costs
Prostate
Hormones
Carcinoma
Incidence

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Moorthy, Krishna H. ; Prabhu, G. G.Laxman ; Venugopal, P. / The resurgence of estrogens in the treatment of castration-resistant prostate cancer. In: Indian Journal of Urology. 2019 ; Vol. 35, No. 3. pp. 189-196.
@article{7f6fc0b3b0454a1b86eb9a928d6a2e4a,
title = "The resurgence of estrogens in the treatment of castration-resistant prostate cancer",
abstract = "Use of exogenous estrogens in manipulating the androgenestrogen equilibrium was one of the earliest therapeutic strategies developed to treat prostate cancer which followed close on heels the discovery of hormone dependence of this tumor. Despite its well-documented benefit, estrogen therapy fell out of favor with the advent of other forms of androgen deprivation therapy (ADT) as the former registered a higher incidence of cardiovascular complications and poorer overall survival. Clearer understanding of the mechanism of action of estrogen coupled with the adoption of alternative routes of administration has triggered a renewed interest in estrogen therapy. Since then, many studies have not only proved the therapeutic benefit of estrogens but also explored the ways and means of minimizing the dreaded side effects deterring its use. Further, the fact that estrogen therapy offered a clear advantage of reduced cost of treatment over other treatments has led many countries to readopt it in the treatment of advanced prostatic cancer. We reviewed the published data on the use of estrogens in CRPC, which may affect its revival as an efficacious treatment option having minimal side effects, with modified dosage and route of administration. Estrogen therapy would be a less expensive option having equivalent or even better therapeutic effect than ADT in advanced carcinoma of prostate.",
author = "Moorthy, {Krishna H.} and Prabhu, {G. G.Laxman} and P. Venugopal",
year = "2019",
month = "7",
day = "1",
doi = "10.4103/iju.IJU-56-19",
language = "English",
volume = "35",
pages = "189--196",
journal = "Indian Journal of Urology",
issn = "0970-1591",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

The resurgence of estrogens in the treatment of castration-resistant prostate cancer. / Moorthy, Krishna H.; Prabhu, G. G.Laxman; Venugopal, P.

In: Indian Journal of Urology, Vol. 35, No. 3, 01.07.2019, p. 189-196.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The resurgence of estrogens in the treatment of castration-resistant prostate cancer

AU - Moorthy, Krishna H.

AU - Prabhu, G. G.Laxman

AU - Venugopal, P.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Use of exogenous estrogens in manipulating the androgenestrogen equilibrium was one of the earliest therapeutic strategies developed to treat prostate cancer which followed close on heels the discovery of hormone dependence of this tumor. Despite its well-documented benefit, estrogen therapy fell out of favor with the advent of other forms of androgen deprivation therapy (ADT) as the former registered a higher incidence of cardiovascular complications and poorer overall survival. Clearer understanding of the mechanism of action of estrogen coupled with the adoption of alternative routes of administration has triggered a renewed interest in estrogen therapy. Since then, many studies have not only proved the therapeutic benefit of estrogens but also explored the ways and means of minimizing the dreaded side effects deterring its use. Further, the fact that estrogen therapy offered a clear advantage of reduced cost of treatment over other treatments has led many countries to readopt it in the treatment of advanced prostatic cancer. We reviewed the published data on the use of estrogens in CRPC, which may affect its revival as an efficacious treatment option having minimal side effects, with modified dosage and route of administration. Estrogen therapy would be a less expensive option having equivalent or even better therapeutic effect than ADT in advanced carcinoma of prostate.

AB - Use of exogenous estrogens in manipulating the androgenestrogen equilibrium was one of the earliest therapeutic strategies developed to treat prostate cancer which followed close on heels the discovery of hormone dependence of this tumor. Despite its well-documented benefit, estrogen therapy fell out of favor with the advent of other forms of androgen deprivation therapy (ADT) as the former registered a higher incidence of cardiovascular complications and poorer overall survival. Clearer understanding of the mechanism of action of estrogen coupled with the adoption of alternative routes of administration has triggered a renewed interest in estrogen therapy. Since then, many studies have not only proved the therapeutic benefit of estrogens but also explored the ways and means of minimizing the dreaded side effects deterring its use. Further, the fact that estrogen therapy offered a clear advantage of reduced cost of treatment over other treatments has led many countries to readopt it in the treatment of advanced prostatic cancer. We reviewed the published data on the use of estrogens in CRPC, which may affect its revival as an efficacious treatment option having minimal side effects, with modified dosage and route of administration. Estrogen therapy would be a less expensive option having equivalent or even better therapeutic effect than ADT in advanced carcinoma of prostate.

UR - http://www.scopus.com/inward/record.url?scp=85068756280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068756280&partnerID=8YFLogxK

U2 - 10.4103/iju.IJU-56-19

DO - 10.4103/iju.IJU-56-19

M3 - Review article

VL - 35

SP - 189

EP - 196

JO - Indian Journal of Urology

JF - Indian Journal of Urology

SN - 0970-1591

IS - 3

ER -